SEC Filing Summary: Catalyst Biosciences, Inc. (CBIO)
Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on January 26, 2021. The registrant is a Delaware corporation with its principal executive offices in South San Francisco, CA. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Note: The request metadata referenced "Gyre Therapeutics," but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation update rather than a financial statement filing.
Material Changes
On January 26, 2021, the Company posted an update to its corporate presentation on its investor relations website. This update is furnished under Item 7.01 (Regulation FD Disclosure) and is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the corporate presentation (Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. Consequently, the information is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly stated. The filing does not contain specific management commentary, guidance, or risk factors within the text of the 8-K itself.
Investor Verification Checklist
- Verify the content of the updated corporate presentation (Exhibit 99.1) on the company's investor relations website.
- Confirm that the presentation is not considered "filed" information for liability purposes under Section 18 of the Exchange Act.
- Review subsequent filings (e.g., 10-K or 10-Q) for audited or reviewed financial metrics, as this 8-K contains no financial data.